Olema Pharmaceuticals (OLMA) Assets (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Assets of $530.6 million for Q1 2026, up 29.54% year-over-year from $409.6 million in Q1 2025, and down 0.52% quarter-over-quarter from $533.4 million in Q4 2025.
Analysis
Olema Pharmaceuticals (OLMA) Assets (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Assets for 7 consecutive years, with $530.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 29.54% year-over-year to $530.6 million; the TTM figure through Mar 2026 stood at $530.6 million (up 29.54% YoY), while the FY2025 annual figure was $533.4 million, up 18.28% from the prior year.
- Assets retreated to $530.6 million in Q1 2026 per OLMA's latest filing, from $533.4 million in the prior quarter.
- Across five years, Assets topped out at $533.4 million in Q4 2025 and bottomed at $177.6 million in Q2 2023.
- Historically, Assets has averaged $313.3 million across 5 years, with a median of $276.9 million in 2023.
- Annual changes were most pronounced in 2023 — Assets dropped 29.43% — and 2024, when it jumped 62.84%.
- Olema Pharmaceuticals' Assets stood at $215.6 million in 2022, then rose by 28.43% to $276.9 million in 2023, then jumped by 62.84% to $451.0 million in 2024, then grew by 18.28% to $533.4 million in 2025, then slipped by 0.52% to $530.6 million in 2026.
- Business Quant data shows OLMA's Assets at $530.6 million in Q1 2026, $533.4 million in Q4 2025, and $352.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Olema Pharmaceuticals | 1.13 Bn | 1.13 Bn | - | 486.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 486.58 Mn |
| Mar 31, 2026 | 530.65 Mn |
| Dec 31, 2025 | 533.43 Mn |
| Sep 30, 2025 | 352.45 Mn |
| Jun 30, 2025 | 382.00 Mn |
| Mar 31, 2025 | 409.64 Mn |
| Dec 31, 2024 | 450.98 Mn |
| Sep 30, 2024 | 230.17 Mn |
| Jun 30, 2024 | 254.56 Mn |
| Mar 31, 2024 | 263.69 Mn |
| Dec 31, 2023 | 276.95 Mn |
| Sep 30, 2023 | 292.80 Mn |
| Jun 30, 2023 | 177.62 Mn |
| Mar 31, 2023 | 195.77 Mn |
| Dec 31, 2022 | 215.65 Mn |
| Sep 30, 2022 | 232.00 Mn |
| Jun 30, 2022 | 250.60 Mn |
| Mar 31, 2022 | 277.42 Mn |
| Dec 31, 2021 | 295.95 Mn |
| Sep 30, 2021 | 309.80 Mn |